Phage Therapeutic Composition for Gut Methane Reduction in IBS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceuticals used to reduce methane production in humans with irritable bowel syndrome, particularly constipation-predominant IBS, disrupt the enteric microbiome indiscriminately, necessitating a more targeted strategy to alleviate symptoms such as bloating and constipation.
Innovation Solution
Administration of viruses capable of inhibiting methane production in the gastrointestinal tract, specifically targeting Methanobrevibacter smithii, to reduce methane levels without disrupting the enteric microbiome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If pharmaceuticals or antibiotics are used to reduce methane production, then methane levels decrease, but the enteric microbiome is disrupted indiscriminately
Solution Approach 1:
The patent uses bacteriophages as intermediary agents that specifically infect and lyse methanogenic archaea. These phages act as mediators between the therapeutic goal (reducing methane) and the constraint (preserving microbiome integrity), providing targeted action without broad-spectrum disruption. The phages selectively bind to and infect only methanogen cells, leaving other gut microbiota unaffected.
Solution Approach 2:
The invention applies local quality by confining the therapeutic action to specific methanogenic archaea populations rather than affecting the entire microbiome uniformly. The bacteriophages exhibit host-specificity, concentrating their lytic activity only on methanogens while preserving the diversity and function of other gut microorganisms. This localized action resolves the contradiction between methane reduction and microbiome preservation.
2Ease of operation
If antibiotics are used to reduce methane production, then constipation symptoms improve, but harmful side effects increase due to indiscriminate effects
Solution Approach 1:
Bacteriophages serve as highly specific intermediaries that deliver the therapeutic effect (methane reduction and symptom relief) without the harmful side effects associated with antibiotics. The phages naturally target only methanogenic archaea through receptor-specific binding, eliminating the need for broad-spectrum antibiotic activity and thereby avoiding associated side effects such as resistance development and microbiome disruption.
Solution Approach 2:
The invention changes the fundamental parameter of specificity from low (antibiotics affecting broad ranges of microorganisms) to high (phages targeting specific methanogen species). This parameter change transforms the therapeutic approach from non-specific inhibition to precise targeting, achieving symptom relief while eliminating the harmful side effects that arise from indiscriminate microbial killing.
3Quantity of substance
If broad-spectrum agents are used to reduce methane, then production decreases, but microbiome diversity is reduced
Solution Approach 1:
The bacteriophages act as selective intermediaries that reduce methane production while preserving microbiome diversity. Their host-specific infection mechanism ensures that only methanogenic archaea are affected, maintaining the stability and diversity of the broader microbiome composition. This resolves the contradiction by providing a mechanism that achieves methane reduction without the collateral damage to microbial diversity caused by broad-spectrum agents.
Solution Approach 2:
The invention applies local quality by restricting the therapeutic action to the specific niche of methanogenic archaea within the microbiome. The phages concentrate their lytic activity locally on methanogen cells, leaving other microbial communities intact and preserving overall microbiome diversity. This localized approach contrasts with broad-spectrum agents that uniformly affect multiple microbial taxa.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces methane production effectively, alleviating symptoms of constipation and discomfort in C-IBS patients by targeting the specific methanogens responsible for elevated methane production.
Implementation Method 1
The viruses infect M. smithii cells, replicate within them, and cause cell lysis, releasing progeny viruses into the environment.
Implementation Method 2
Methanogenic archaea (commonly referred to as methanogens) are the predominant biological sources of methane in nature and Methanobrevibacter smithii is the predominant methanogen in the human intestine.
Data Source
AI summary
The present disclosure relates to the reduction of methane production in humans, in particular humans suffering from irritable bowel syndrome. The disclosure provides viruses capable of inhibiting the formation of methane in vivo in the gastrointestinal tract of a human. The disclosure also provides compositions, including pharmaceutical compositions, comprising a virus capable of reducing the formation of methane in vivo in the human gastrointestinal tract. The disclosure further provides methods of reducing the production of methane in humans, comprising administering to the human a virus capable of inhibiting the production of methane in vivo in the gastrointestinal tract.